• Acumen Pharmaceuticals highlighted sabirnetug (ACU193), an intravenous monoclonal antibody designed to selectively target toxic amyloid beta oligomers in early Alzheimer’s disease.
• ALTITUDE-AD Phase 2 trial is fully enrolled with 542 patients; topline results expected late 2026.
• Cash, cash equivalents, marketable securities totaled about $128 million as of March 31, 2026; cash runway expected to extend into early 2027.
• Program update included EBD enhanced brain delivery platform for oligomer-targeted antibodies using BBB-penetrating technology; preclinical candidate data disclosed early 2026; IND filing targeted for mid-2027.
• Phase 1 data cited low ARIA-E incidence at about 10%, with no ARIA-E observed in ApoE4 homozygotes in a subgroup of 6 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.